XiaoMi-AI文件搜索系统
World File Search Systemactionable
主要的研发管道
AGA: actionable genomic alterations, BC: breast cancer, CRC: colorectal cancer, CRPC: castration-resistant prostate cancer, ESCC: esophageal squamous cell carcinoma, ES-SCLC: extensive stage-small cell lung cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, SCCHN: squamous cell carcinoma of head and neck, SCLC：小细胞肺癌，TNBC：三重阴性乳腺癌
主要研发管道：5DXD ADC
AGA: actionable genomic alterations, BTC : biliary tract cancer, BC: breast cancer, CRC: colorectal cancer, CRPC: castration-resistant prostate cancer, ESCC: esophageal squamous cell carcinoma, ES-SCLC: extensive stage-small cell lung cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, SCCHN: squamous cell头颈癌，SCLC：小细胞肺癌，TNBC：三重阴性乳腺癌
Genetics and beyond
Abstract: Advances in molecular tumor diagnostics have transformed cancer care. However, it remains unclear whether precision oncology has the same impact and transformative nature across all malignancies. We conducted a retrospective analysis of patients with human papillomavirus (HPV)-related gynecologic malignancies who underwent comprehensive molecular profiling and subsequent discussion at the interdisciplinary Molecular Tumor Board (MTB) of the University Hospital, LMU Munich, between 11/2017 and 06/2022. We identified a total cohort of 31 patients diagnosed with cervical (CC), vaginal or vulvar cancer. Twenty-two patients (fraction: 0.71) harbored at least one mutation. Fifteen patients (0.48) had an actionable mutation and fourteen (0.45) received a recommendation for a targeted treatment within the MTB. One CC patient received a biomarker- guided treatment recommended by the MTB and achieved stable disease on the mTOR inhibitor temsirolimus for eight months. Factors leading to non-adherence to MTB recommendations in other patient cases included informed patient refusal, rapid deterioration, stable disease, or use of alternative targeted but biomarker-agnostic treatments such as antibody–drug conjugates or checkpoint inhibitors. Despite a remarkable rate of actionable mutations in HPV-related gynecologic malignancies at our institution, immediate implementation of biomarker-guided targeted treatment recommendations remained low, and access to targeted treatment options after MTB discussion remained a major challenge.
阿斯利康肿瘤学护士教育计划
• Lung Cancer Disease Overview (7 slides) • The Importance of Biomarker Testing in Patients with Resectable NSCLC (15 slides) • The Importance of Comprehensive Biomarker Testing in Patients with Metastatic NSCLC (12 slides) • Integrating Liquid Biopsy Testing to Help Identify Actionable Variant Genes in Patients With Metastatic NSCLC (11 slides) • The Importance of Knowing All Biomarker Test Results Prior to转移性NSCLC的治疗起始（11个幻灯片）•通过多学科团队方法（12个幻灯片）优化肺癌患者护理•转移性NSCLC患者接受EGFR TKIS的不良反应管理（14个幻灯片）
在...
40 mg胶囊剂型。Engineered using cutting-edge PCR technology, the AmoyDx® PLC Panel enables the simultaneous detection of activation alterations across 11 critical driver genes ( EGFR , ALK , ROS1 , KRAS , BRAF , HER2 , RET , MET , NTRK1 , NTRK2 , NTRK3 ) and identifies actionable mutations in seven of these genes ( EGFR , ALK , ROS1 , BRAF , MET ex14 skipping, KRAS，RET）直接与16种目标NSCLC疗法相关。该批准表示在精确癌症治疗中向前迈出的变革一步，将快速，敏感的检测与显着增强的潜力相结合
clinpgx-2024-agenda.pdf
03 - Preemptive Return of Clinical Pharmacogenomic Results to Over 50,000 Individuals in a Population-scale Biobank: Phenotype and Actionable Medication Exposure Characteristics James L Martin, PharmD , MPH1,2, Kristy R Crooks, PhD1, 3, Casey S Greene, PhD1,3, Ashley Hansen, RN, BSN4, Emily C Hearst, MHSA1,4, Kaitlyn W Hess，MS，MLS（ASCP）CM，4，Natalie Johnson，PharmD4，David P Kao，MD1,3，Elizabeth L Kudro N，MD，MPH1，MPH1，3，Yee Ming Lee，Pharmd1，2 RN4，Anna Tanaka，BA1,4，Katy Trinkley，PharmD，PHD1，3，Sharon Vandenberg，RPH，MBA4，Christina L Aquil Ante，PharmD1，2
11th Cancer Biology Retreat 2024
Danina Kuster , Institute of Molecular Cancer Research, UZH Non-Canonical Mechanisms of Breast Tumorigenesis in BRCA2 Mutation Carriers Laura Leuenberger , Department of Medical Oncology and Hematology, USZ Investigating actionable vulnerabilities of clear cell sarcoma by whole- genome CRISPR/Cas9 knock-out screening Charbel Machaalani , Division of Oncology, Kispi Molecular and Spatial Insights into Treatment Failure in Pediatric Low- Grade Gliomas Giovanni Papa , Institute of Molecular Cancer Research, UZH In vivo and in vitro organoid-based CRISPR screening for gastric tumor suppressors 16:55 Check-in 18:00-19:30 Dinner 19:30-21:30 Poster session 1 (Posters 1-24) Poster Committee: Matthias Altmeyer, Maries van den Broek, Ana GuerreiroStücklin，Michael Hottiger，Mitch Levesque，Massimo Lopes，Enni Markkanen，AnneMüller，Javad Nazarian，Karina Silina
内布拉斯加州全州网络安全计划
Representatives from the Nebraska Association of County Officials, The League of Municipalities, Nebraska Public Power District, Educational Service Unit Coordinating Council, University of Nebraska, Representation from Public Health Organizations, Nebraska Emergency Management and Emergency Management Departments from across the state of Nebraska, as well as the Nebraska National Guard and Office of the CIO have all collaborated to develop and update the Cybersecurity Plan with actionable and旨在确定成功完成的敬业冠军的可衡量目标和目标。这些目标和目标集中在整个州的网络安全，确定安全差距，建立关键治理主题，促进网络安全最佳实践以及行使计划和能力的情况下的识别。他们旨在支持内布拉斯加州计划新技术并导航不断变化的网络安全景观，同时结合SLCGP所需的计划元素。
国家癌症药物基金列表Ver1.333 20-Nov-24
5。该患者已被记录为具有可起诉突变的NSCLC：EGFR 19或21，EGFR外显子20，ALK，ROS1，ROS1，RET，KRAS G12C，MET14。Please mark in the box below whether such an actionable mutation has been found or not: - only testing for an EGFR 19 or 21 mutation has been done and the result is negative - genomic testing has not been done for all the genomic alterations listed below and results so far have been negative - the patient's NSCLC is positive for an EGFR 19 or 21 mutation - the patient's NSCLC is positive for an EGFR exon 20 mutation - the patient's NSCLC is positive for a ALK gene fusion - the patient's NSCLC is positive for a ROS1 gene rearrangement - the patient's NSCLC is positive for a RET gene fusion - the patient's NSCLC is positive for a KRAS G12C mutation - the patient's NSCLC is positive for a MET exon 14 skipping mutation
采用预测性生物标志物的不同方法
可操作基因在预测索拉非尼疗效中的作用。方法：通过定量实时逆转录 PCR，我们分析了 220 例接受索拉非尼治疗的 HCC 患者的肿瘤与非癌组织中 7 种可操作基因（ VEGFR2 、 PDGFRB 、 c-KIT 、 c-RAF 、 EGFR 、 mTOR 和 FGFR1 ）的表达水平。我们的分析发现，与无反应者相比，9 名反应者并没有独特的临床特征。受试者操作特征曲线评估了根据可操作基因计算的治疗效益评分 (TBS) 的预测性能。结果：反应者的 TBS 值明显高于无反应者。曲线下面积为 0.779，mTOR 与 VEGFR2 、 c-KIT 和 c-RAF 相结合的 TBS 是索拉非尼疗效的最显著预测因子。索拉非尼单独使用时，HCC 患者的反应率为 0.7–3%，但当根据可操作基因对患者进行分层时，肿瘤反应率上升至 15.6%。此外，可操作基因表达与肿瘤反应显着相关。结论：我们根据可操作分子亚型对患者进行分层的研究结果可能为提高索拉非尼治疗 HCC 的有效性提供一种治疗策略。